Annals of Oncology 15:759-764, 2004
© 2004 European Society for Medical Oncology
Original Paper |
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial
Received 18 July 2003; revised 28 December 2003; accepted 22 January 2004Background:
A phase I–II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continuous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer.
Patients and methods:
Patients with measurable unresectable and/or metastatic gastric carcinoma, World Health Organization performance status 
1, normal hematological and renal functions, adequate hepatic function and not pretreated for advanced disease by chemotherapy, received up to eight cycles of a combination of docetaxel on day 1, cisplatin on day 1 and 5-FU p.i.v. on days 1–14 (TCF) every 3 weeks, which was escalated up to the MTD, defined by the occurrence of dose-limiting toxicity in two patients in one dose level.
Results:
Fifty-two patients were accrued and treated (43 in the phase I part of the trial and nine additional at the recommended dose level). A median of five cycles/patient was given. The recommended dose of TCF was docetaxel 85 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1 and 5-FU p.i.v. 300 mg/m2/day on days 1–14. Grade 
3 toxicities were neutropenia 79%, alopecia 46%, fatigue 23%, mucositis 10%, diarrhea 19%, nausea/vomiting 13%, neurological 4% and palmar-plantar 2%. Ten non-fatal febrile neutropenia episodes were recorded in eight patients. There were no treatment-related deaths. Among 41 patients with measurable disease (79%), we observed one complete and 20 partial responses for an overall intent-to-treat response rate of 51% (95% confidence interval 35–67%). Five patients (20%) had stable disease for 12 weeks (four cycles). The median overall survival was 9.3 months.
Conclusions:
5-FU p.i.v. at 300 mg/m2/day for 2 weeks out of three could be safely added to the docetaxel–cisplatin (TC) combination, but the dose of docetaxel had to be reduced to 75 mg/m2 in a subsequent phase II trial. This drug regimen seems to be very active in advanced gastric cancer. Comparison with both TC and ECF in a randomized SAKK trial is ongoing.
1 Oncosurgery, Department of Surgery, Hôpital Cantonal Universitaire, Geneva; 2 SIAK Coordinating Center, Bern, Switzerland; 3 Department of Medicine, European Institute of Oncology, Milan, Italy; 4 Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona; 5 Multidisciplinary Oncology Center, University Hospital (CHUV), Lausanne; 6 Division of Oncology, Department of Medicine C, Kantonspital; 7 Division of Oncology, Department of Medicine, Kantonspital, Basel; 8 Institute of Medical Oncology, Inselspital, Bern; 9 Oncology Institute of Southern Switzerland, Ospedale Civico, Lugano, Switzerland
Key words: chemotherapy, docetaxel, gastric cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. D. Roth, N. Fazio, R. Stupp, S. Falk, J. Bernhard, P. Saletti, D. Koberle, M. M. Borner, K. Rufibach, R. Maibach, et al. Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research J. Clin. Oncol., August 1, 2007; 25(22): 3217 - 3223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Lutz, H. Wilke, D.J. T. Wagener, U. Vanhoefer, K. Jeziorski, S. Hegewisch-Becker, L. Balleisen, E. Joossens, R. L. Jansen, M. Debois, et al. Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 20, 2007; 25(18): 2580 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kim, J.-H. Park, S.-J. Bang, D.-H. Kim, H. R. Cho, G. Y. Kim, and Y. J. Min A Phase II Study of Docetaxel and Cisplatin in Patients with Gastric Cancer Recurring After or Progressing During 5-FU/Platinum Treatment Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lim, M. Michael, G. B. Mann, and T. Leong Adjuvant Therapy in Gastric Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, M. B. Fodor, S. A. Tjulandin, V. M. Moiseyenko, Y. Chao, S. C. Filho, A. Majlis, S. Assadourian, and E. Van Cutsem Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma J. Clin. Oncol., August 20, 2005; 23(24): 5660 - 5667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|